Clinical Trial Update: An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris [Phase 3]

View source ↗

Summary

Open-label long-term extension evaluating the safety of CB-03-01 cream 1% in acne vulgaris; completed Phase 3 trial with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acne Vulgaris

Drugs mentioned

• CB-03-01 cream, 1% (CB-03-01)

Snippet

Sponsor: Cassiopea SpA | Conditions: Acne Vulgaris | Phase 3 | Status: COMPLETED | Results posted: 2020-11-17